Background: Current treatment guidelines recommend the use of tenofovir (TDF) and emtricitabine (FTC) along with a third agent to treat HIV-positive adults. However, other treatment options, including the use of abacavir (ABC) and lamivudine (3TC) when used with ritonavir-boosted darunavir (DRV/r), have rarely been studied. Objective: We evaluated the safety and effi cacy of the coformulation of ABC/3TC administered with DRV/r in treatment-naïve and treatment-experienced patients. Methods: HIV-infected adults who received an open-label combination of ABC/3TC/ DRV/r were followed in a community clinic in Montréal. Patients had no resistance to any of the compounds in their regimen. Viral load (VL), CD4 cell count, AST, ALT, and creatinine levels were examined throughout the 48 weeks of follow-up. Results: Sixty-seven patients with a mean age of 45 years were enrolled. Two did not return for follow-up and were excluded. Thirty-fi ve (52%) were treatmentexperienced and the remaining were treatment-naïve. HLA-B*5701 test results were available for 56 patients and none were positive. At baseline, mean VL was 4.8 log for treatment-naïve and 2.3 log for experienced patients. Twelve patients discontinued the study regimen prior to reaching the endpoint. At week 48, 79% had a VL <50. Median CD4 cell gain was higher among treatment-naïve patients (273 cells) than among treatment-experienced patients (102 cells) (P = .002). No patient experienced any grade 2 or higher liver enzyme elevation throughout the study. Conclusions: The new combination of ABC/3TC/DRV/r demonstrates a high rate of antiviral activity with no major toxicity. The drug combination appears to be generally safe and well tolerated.
F
or the past 15 years, HIV-infected patients have been treated by a combination of 3 different antiretrovirals (ARV). Currently, the majority of national and international guidelines recommend prescribing 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in addition to a third agent, which can be a non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI), or integrase strand transfer inhibitor (INSTI). [1] [2] [3] [4] [5] [6] [7] The 2010 recommendations of the International AIDS Society-USA Panel placed the coformulation of tenofovir (TDF) and emtricitabine (FTC) as their only recommended dual-NRTI component, with ritonavir-boosted darunavir (DRV/r) as one of their 4 "preferred" third agents. 8 Data from ARTEMIS trial, which found DRV to be safe and efficacious when taken with the aforementioned NRTI coformulation, were used to approve the secondgeneration PI for a fi rst-line therapy. 9 Supported by these fi ndings, the January 10, 2011 version of the US Department of Health and Human Services's (DHHS) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents recommended that this boosted-PI combination be placed among its fi rst-level treatment recommendation ("Preferred Regimens"). 10 However, TDF has been associated with adverse reactions such as nephrotoxicity (including Fanconi syndrome) and musculoskeletal disorders (eg, a reduction of bone mineral density). 11 Thus, for
Montréal, Canada, that follows almost 2,500 HIVpositive patients and specializes in sexually transmitted infection (STI)/HIV treatment. HIV-positive patients taking ABC/3TC in combination with DRV/r who met the eligibility criteria listed below had their data extracted on January 2012.
Study Population
Both treatment-naïve and treatment-experienced patients who began taking ABC/3TC with DRV/r between December 2008 and March 2011 were eligible to be included in the analysis. Patients also needed to have available data on viral load (VL) and CD4 cell counts around the time they began their treatment.
Patients with any documented NRTI or PI primary mutation, as well as treatment-experienced patients who had a documented virological failure prior to starting the regimen of interest, were excluded. Virological failure was defi ned as the inability to achieve or maintain suppression of viral replication to an HIV RNA level <50 copies/mL.
Dosage
The study regimen consisted of ABC 600 mg plus 3TC 300 mg once daily (Kivexa or Epzicom), administered with 2 tablets of darunavir (Prezista) 400 mg and one tablet of ritonavir (Norvir) 100 mg, both coadministered once a day.
Measures
Data on treatment modifi cation, VL, CD4 cell counts, aspartate transaminase (AST), alanine transaminase (ALT), and creatinine levels were collected throughout the 48 weeks of follow-up. Effi cacy of the treatment regimen was assessed by examining the proportion of patients who maintained or achieved an undetectable VL, as well as by examining the changes in CD4 cells count from baseline to the study end. VL was considered to be undetectable if it was below 50 copies/mL. Safety was assessed via hepatic enzymes and renal function throughout the 48 weeks of treatment.
Statistical Analyses
Effi cacy and safety analyses were examined for all the study patients who met the aforementioned patients who are already affected by or at risk of renal or bone complications, other dual-NRTI combinations are required when prescribing DRV/r as a third agent.
Currently, the only other dual-NRTI coformulations that are used for treating patients are the combination of zidovudine (AZT) and lamivudine (3TC) or the combination of abacavir (ABC) and 3TC. However, AZT/3TC has been associated with increased levels of toxicity, including anaemia and mitochondrial dysfunction, and it needs to be taken twice a day. It is therefore considered a preferred regimen only for pregnant women. 1 ABC/3TC has been shown to be as effi cacious and safe as TDF/FTC, 12 yet other researchers have found the combination to be less effi cacious, especially in patients who were treatment-naïve and had a baseline HIV-1 RNA greater than 100,000 copies/mL. 13 Moreover, individuals taking ABC have been found to be at greater risk of cardiovascular problems, 14 and they should be screened for HLA-B*5701 to prevent ABC hypersensitivity. 15, 16 Although these issues need to be taken into consideration before administering ABC/3TC to patients, it is at the moment the only single-pill dual-NRTI fi xed-dosage combination alternative to TDF/FTC, and treatment guidelines include it as a possible treatment regimen. For example the J anuary 10, 2011 version of the DHHS guidelines classifi ed the combination (when taken with DRV/r) in its third-level of treatment recommendations, as there is a lack of defi nitive data to show the safety and effi cacy of this combination. 10 The preliminary (week 24) results of the present study were presented at the International AIDS Society meeting in Rome in July 2011. 17 The fi ndings were used to upgrade the treatment combination from an "acceptable regimen" to an "alternative regimen" in the latest DHHS guidelines. The objectives of this article were to present the data on the safety and effi cacy of the coformulation of ABC/3TC when it is administered with DRV/r, 48 weeks after patients were initially prescribed the regimen.
METHODS

Study Design
A single-center, retrospective, observational open-label study was undertaken at Clinique médi-cale l'Actuel, a community-based clinic located in Baseline characteristics for the 65 remaining patients are shown in Table 1 . Ninety-one percent were male, and 85% were men who had had sex with other men (MSM). Patient mean age was 45 years. The probable route of HIV infection was either unprotected sexual activity (91%) or injection drug use (IDU; 9%). Three percent of patients originated from an endemic country (defi ned as originating from African or Caribbean countries). No data were available on the race or ethnicity of participants.
Patients had a median of 9 visits (range, 2-25 visits) between the time that they began the study regimen and the 48-week endpoint. The median length of time since initially being diagnosed with HIV was 6 years (interquartile range [IQR], [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Almost half of the patients were treatment-naïve before initiating ABC/3TC with DRV/r. Eighty-five percent were screened for HLA, and none of them carried the HLA-B*5701 allele. Four patients were coinfected with the eligibility criteria. Any discontinuation of ABC, 3TC, DRV, or ritonavir (RTV) was counted as a failure in the analysis for each endpoint (ie, intention-to-treat [ITT] analysis). Descriptive statistics were used to examine the characteristics of patients who were enrolled in the study. We also examined differences in the outcomes of interest between those who were initially treatment-naïve and those who were treatment-experienced. Comparisons were done using independent samples t tests, matched-samples t test, or chi-square tests for proportions (all 2-sided). Statistical analyses were performed using SPSS version 17.0 (SPSS, Inc., Chicago, Illinois, USA).
RESULTS
A total of 67 patients initiated the study regimen before March 2011. Two patients had no subsequent visit at the clinic during the study period and were excluded from any further analyses. 
ABC/3TC WITH DRV/R AS A TREATMENT OPTION • TROTTIER ET AL 337
The remaining 52 individuals completed the 48 weeks of treatment.
No signifi cant differences were found among participant characteristics between those who discontinued and those who stayed on the regimen until week 48, except for participant gender: 4 of those who stopped the regimen before week 48 (31%) were women compared with 4% for those who continue until the end of study period (P = .012). Figure 2 shows that 51 patients had an undetectable VL after 48 weeks of treatment (ITT, 79%; on treatment [OT], 98%). Fifty-two patients had a VL below 400 copies/mL (ITT, 80%; OT, 100%). Among those who were treatment-naïve, 25 patients had an undetectable VL after 48 weeks of follow-up (ITT, 81%; OT, 96%); among treatment-experienced patients, 26 had an undetectable VL (ITT, 77%; OT, 100%). This difference was not statistically signifi cant (P = .459).
Effi cacy of ABC/3TC-DRV/r
Eighteen patients (28%) had a baseline VL of 100,000 copies/mL or more (all were treatmentnaïve), and the remaining 47 (72%) had a baseline VL below 100,000 copies/mL. Among those who had a baseline VL of 100,000 copies/mL or more, 79% achieved an undetectable VL at week 48; whereas 82% of individuals who had a baseline VL hepatitis C virus. The median CD4 at baseline was 390 cells/mm 3 with a nadir of 290 cells/mm 3 . Prior to the study, naïve patients had a mean VL of 4.8 log copies/mL, and most of the treatmentexperienced patients had an undetectable VL (79%). Among treatment-experienced patients, 7 (21%) had a baseline VL >50 copies/mL. Of those 7 patients, 4 were in treatment interruption and 3 were switched from other regimens before achieving virologic control due to intolerance to the previous treatment combination.
The previous treatment combinations mostly consisted of 2 NRTIs and 1 PI. As depicted in Figure 1 , 26 patients changed their third agent from either lopinavir/r (n = 11), fosamprenavir/r (n = 7), atazanavir/r (n = 6), or atazanavir (n = 2) to DRV. One patient had only the backbone switched for toxicity reason, and 6 patients had their entire regimen changed.
Thirteen individuals (20%) switched to a different regimen prior to the 48-week endpoint. Eight were due to adverse events, and 5 for other reasons. Experienced adverse events were allergies (n = 4), gastrointestinal problems (n = 3), and lipodystrophy (n = 1). Other reasons for stopping the treatment were a pregnancy, lack of funds to pay for the medication, travelling abroad, and interactions with other drugs taken by the patient. One patient died of colon cancer approximately 30 weeks after beginning the treatment. discontinued the study combination due to a rash or allergy, and 5% discontinued for gastrointestinal problems. One patient discontinued treatment with ABC/3TC-DRV/r due to lipodystrophy. This patient had been diagnosed as HIV-positive in the 1980s, had been previously treated with other ARVs for 14 years, and had been known to have previous lipid abnormalities.
No patient experienced any grade 2 or higher liver enzyme elevations throughout the course of the entire study. Grade 1 ALT elevation occurred in 8 patients and grade 1 AST elevation in 4 patients. Hyperbilirubinemia occurred in 6 patients (1, grade 2; 5, grade 1). Creatinine elevation was seen in 8 patients (1, grade 2; 7, grade 1).
As previously mentioned, one patient died during the observational period of colon cancer. However, this death was deemed unrelated to the ARV treatment.
of less than 100,000 copies/mL achieved or remained undetectable at week 48 (P = .571).
The median CD4 cell gain after 48 weeks was 170 cells/mm 3 (IQR, 60-328 cells/mm 3 ). Depicted in Figure 3 is the comparison in the median CD4 increase between treatment-naïve and treatment-experienced patients. In comparison with those who were treatment-experienced, persons who were treatment-naïve had a signifi cantly higher mean increase in CD4 cell counts at the end of the study period (272 vs 102 cells/mm 3 ; P = .004). Table 2 shows the incidence of drug-related adverse reactions that led to the discontinuation of the study medication, as well as abnormal laboratory data over the study period. Six percent combination achieved a virologic control rate in 79% of individuals, regardless of the treatment status of the patient. Even though this group consisted of 2 separate populations, they were combined in the analysis as they both share commonalities such as no primary resistance to the study drugs and no previous virological failure. We also observed a mean increase of 272 CD4 cells among treatmentnaïve patients. Treatment-experienced patients also showed a slight improvement in their level of immunity at the end of the study period. These results differ slightly from what was observed in other studies. Notably, the ARTEMIS study showed that 84% of patients who initiated TDF/FTC with DRV/r reached virological suppr ession at the end of the study period. However, only patients who were treatment-naive were included in this trial. The results of that trial also showed a slightly lower CD4 cell gain in comparison to what was observed in our study (184 cells/mm 3 vs 272 cells/mm 3 ). 9 The TITAN study, which investigated the efficacy of TDF/FTC in combination with DRV/r in treatment-experienced but lopinavir-naive patients, found that 71% of patients achieved a virologic suppression after 48 weeks of treatment. They also showed a CD4 gain of 88 cells/mm 3 . 
Safety of ABC/3TC-DRV/r
DISCUSSION
In this study, the safety and effi cacy of ABC and 3TC in combination with DRV/r was evaluated in both treatment-naïve and treatment-experienced patients. Our results show that this treatment We also decided to include patients in the study who had at least one follow-up visit after starting the study regimen. Although this methodology does not conform to typical ITT analyses, we felt this was the best way to measure whether or not the patients took their medication and for us to evaluate the effi cacy and safety of the regimen.
The usual clinical follow-up is for the patient to return 1 month after receiving a new medication and then every 3 months thereafter. However, as this was not a trial that included regular clinical appointments, the number of visits was highly variable. There is thus the possibility that persons who visited the clinic more frequently were more likely to have laboratory abnormalities detected and to experience more adverse events in comparison to those who did not visit the clinic as frequently. However, the mean number of visits between those who experienced at least one laboratory abnormality and those who did not was highly statistically nonsignifi cant (data not shown), thus providing confi dence that the number of visits did not infl uence the detection of abnormalities.
CONCLUSION
In conclusion, the use of ABC/3TC with DRV/r in treatment-naïve and treatment-experienced patients with no prior resistance to the study drugs showed high levels of effi cacy and demonstrated a good safety profi le. The results support the further examination of the use of this combination in fi rstline therapy and switches for HIV-infected adults.
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A recently published study by Nishijima et al, which examined the effi cacy of ABC/3TC-DRV/r but only in treatment-naïve patients, demonstrated a smaller virologic control compared to our study. The trial showed that about 67% of those who continued treatment had an undetectable VL at week 48. However, due to the limited sample size of the study (n = 22), it is diffi cult to make meaningful comparisons. 19 Some of the patients in our study discontinued at least one of the medications of interest prior to reaching the 48-week endpoint. Most discontinuations were due to adverse reactions such as gastrointestinal disorders or due to factors that were extraneous to the medication that was being studied. We observed no cases of ABC hypersensitivity. The percentage of individuals who discontinued their regimen is not abnormal; the percentage of individuals who stopped their treatment varied between the 12% and 16% in the ARTEMIS study 9 and 21% and 29% in the TITAN study. 18 The percentage of those who discontinued is comparable to what was observed in Nishijima et al's study. 19 As mentioned in the introduction, it is important to note that the fi nal results from week 48 are similar to our preliminary results, and thus they support the treatment guideline modification. Although the results are promising, important limitations need to be addressed.
As this was an observational study, certain biases may have infl uenced these results. For example, no system was in place to trace any patients who were lost to follow-up. Patients were not randomized to their treatment, and no suitable controls were examined in this study. Future studies may want to consider these points.
It is important to remember that the relatively small sample size negates the ability to conclusively detect statistically signifi cant differences between treatment-naïve and treatment-experienced patients. A post hoc power analysis found that some of the comparisons undertaken lacked the necessary statistical power to detect a signifi cant difference. However, this was only a preliminary study, and our fi ndings indicate that a larger clinical trial using a greater number of patients is warranted.
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